Bibliography: library/10665-117378

The reference for library/10665-117378 (who-iris) and any references extracted from it. library · All references.

Export these 17 references: BibTeX · CSL-JSON · RIS · Dublin Core XML · Dublin Core / BIBO JSON-LD

✍ + Add reference (standalone node)

Build a standalone folio-reference/v1 node at references/reference.jsonld from fields or pasted BibTeX / CSL-JSON.



· ✍ Create standalone node on GitHub · Download .jsonld · Download .csl.json ·

17 shown

  1. Ahmed, A.A.; Latoundji, S. (2007). [Pilot study of antiretroviral therapy in Djibouti].
    10665-117378 · catalogue · link · repository record · source: catalogue/records/10665-117378.dc.json · held: library/10665-117378
    export: BibTeX · RIS · CSL-JSON · DC XML
  2. Rapport sur l'épidémie mondiale de SIDA. 4ème rapport mondial. Programme com-mun des Nations Unies sur le VIH/SIDA (ONUSIDA). Genève, 2004.
    · extracted · source: references/10665-117378.page-011.1.json
  3. The 3 by 5 initiative (http://www.who.int/3by5/en, consulté le 17 avril 2007).
    · extracted · link · source: references/10665-117378.page-011.2.json
  4. Laurent C et al. The Senegalese govern-ment's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS, 2002, 16:1363-70.
    · extracted · source: references/10665-117378.page-011.3.json
  5. Zekeng P. Contribution au suivi biologi-que des malades de l'Initiative béninoise d'accès aux ARV [Thèse de médecine]. Cotonou, 2003, N° 1075 : 128.
    · extracted · source: references/10665-117378.page-011.4.json
  6. Ganiou R. Étude de suivi des PVVIH sous traitement antirétroviral dans le cadre de l'Initiative béninoise d'accès aux ARV [Thèse de médecine]. Cotonou, 2003, N° 1066 : 90.
    · extracted · source: references/10665-117378.page-011.5.json
  7. Ahmed A. Les infections opportunistes au cours de l'infection VIHISIDA à Djibouti [Thèse de médecine]. Cotonou, 1998, N° 753 : 103.
    · extracted · source: references/10665-117378.page-011.6.json
  8. Okome-Nkoumou M, Mbounja-Loclo ME, Kombila M. Panorama des affections op-portunistes au cours de l'infection par le VIH à Libreville, Gabon. Cahier d'études et de recherches francophones/Santé, 2000, 10(5):329-37.
    · extracted · source: references/10665-117378.page-011.7.json
  9. Vigan J. Affections opportunistes et rap-port avec le taux de CD4 [Thèse de mé-decine]. Cotonou, 2002, N° 1019 : 124.
    · extracted · source: references/10665-117378.page-011.8.json
  10. Bekker LG et al. Antiretroviral therapy in a community clinic - early lessons from a pi-lot project. South African medical journal, 2003, 93(6):458-62.
    · extracted · source: references/10665-117378.page-011.9.json
  11. Hellinger J et al. A pilot study of saqui-navir-SGC (SQV) and lopinavirritonavir (LPVIR) twice daily in protease inhibitor (PI) naive HIV+ individuals: protease inhi-bitor concentrations and week 24 results. Paper presented at the 2% IAS Conferen-ce on HIV Pathogenesis and Treatment, Paris, 13-17 July, 2003.
    · extracted · source: references/10665-117378.page-011.10.json
  12. Negredo E et al. Virological, immunologi-cal, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immuno-deficiency virus infection and longlasting viral suppression. Clinical infectious di-seases, 2002, 34:504—10.
    · extracted · source: references/10665-117378.page-011.11.json
  13. Phillips AN et al. For the Swiss HIV Cohort Study, The Frankfurt HIC Clinic Study and the EuroSIDA, Study Group. Journal of the American Medical Association, 2001, 286:2560-7.
    · extracted · source: references/10665-117378.page-011.12.json
  14. Hoggs RS et al. Rates of diseases pro-gression by baseline CD4 cell count and viral load after initiating triple-drug the-rapy. Journal of the American Medical Association, 2001, 286:2568-77.
    · extracted · source: references/10665-117378.page-011.13.json
  15. Sterling TR, Chaisson RE, Moore RD. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretro-viral therapy. A/DS, 2001, 15:2251-7. Yes V et ol he EU Al Aa ill ioliue clou ll Ga aol all Eastern Mediterranean Health Journal, Vol. 13, No. 6, 2007
    · extracted · source: references/10665-117378.page-011.14.json
  16. Chêne G et al. Change in CD4+ cell count and the risk of opportunistic infection or death after highly active antiretroviral treatment. A/IDS, 1998, 12(17):2313-20. Badri M, Wood R. Usefulness of total lym-phocyte count in moritoring highly active antiretroviral therapy in resource-limited settings. A/IDS, 2003, 17:541-5. Jacobson MA et al. Absolute or total lym-phocyte count as a marker for the CD4 T lymphocyte criterion for initiating antiretro-viral therapy. A/IDS, 2003, 17(6):917-9. Lorenzi P. Impact of drug resistance mu-tations on virologic response to salvage therapy. AIDS, 1999, 13:17-21. Piketty C et al. Phenotypic resistance to protease inhibitors in patients who HAART predicts the outcome at weeks
    · extracted · source: references/10665-117378.page-011.19.json
  17. twelve of five-drug combination including ritonavir, saquinavir and efavirenz. AIDS, 2000, 14:626-8. Boden D et al. HIV1 resistance in newly in-fected individuals. Journal ofthe American Medical Association, 1999, 282:1135-41. Havlir D et al. Drug susceptibility in HIV infection after rebound in patients recei-ving indinavir containing regimen. Journal of the American Medical Association, 2000, 283:229-34. Akakpo J. Effets indésirables des thé-rapies antirétrovirales chez les patients traités à Cotonou [Thèse de médecine]. Cotonou, 2004, N° 1087 : 87. Carr À, Cooper DA. Adverse effects of antiretroviral therapy. Lancet, 2000, 356:1423-30.
    · extracted · source: references/10665-117378.page-011.23.json